NICE consultation on denosumab

14th June 2012

The National Institute for Health and Clinical Excellence (NICE) has issued a second appraisal consultation document on the use of denosumab as a treatment to delay or prevent skeletal-related events in people with bone metastases from solid tumours. This follows the committee’s reconsideration of evidence in light of information received during the first consultation. The latest draft guidance makes the following preliminary recommendations:

• denosumab is recommended as an option for preventing skeletal-related events in adults with bone metastases from breast cancer, if the manufacturer provides denosumab with the discount agreed in the patient access scheme

• denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer

• denosumab is recommended as an option for preventing skeletal-related events in adults with bone metastases from solid tumours other than breast and prostate if zoledronic acid or disodium pamidronate would otherwise be prescribed for these patients and the manufacturer provides denosumab with the discount agreed in the patient access scheme

• adults with bone metastases from solid tumours currently receiving denosumab for the prevention of skeletal-related events that is not recommended according to the above, should be able to continue treatment until they and their clinician consider it appropriate to stop.

The consultation period runs until 2 July 2012 and document can be accessed from the link below.

click here to view